The « Premium Drug Profiling » offers to the investors and TTOs involved in the emergence of new therapies, an independent evaluation during due diligence phases, enabling them to secure their investments.
ProfileHIT represents a unique opportunity for its customers to directly assess in vitro, the response of a drug candidate on the Human vascular peripheral system, before its first administration in Human.
As our screening-strategy can be done before the clinical trials-phase I, it represents a unique opportunity to directly assess the potential of a compound on its future market and to exclude further investments in a non-marketable drug.
